Näiden koulutusten sisältö on Novo Nordiskista riippumattoman sisällöntuottajan tuottamaa. Osa koulutuksista on EACCME-akkreditoituja, joten niitä voidaan lukea hyväksi joidenkin erikoisalojen erikoistumisopinnoissa ja diabeteksen erityispätevyyttä suoritettaessa. Pisteiden kelpoisuus täytyy kuitenkin varmistaa koulutuksesta vastaavalta taholta. Novo Nordisk ei vastaa koulutusten sisällöstä. Osa koulutusten järjestäjistä vaatii luomaan erilliset tunnukset omalle sivustolleen.
This course is developed by Medscape Education Global. Medscape is one of the leading digital platforms for medical education. A comprehensive array of innovative formats, in multiple languages, insures the right educational solution is available to best achieve desired objectives—from text-based articles to state-of-the-art multimedia formats and the most sophisticated simulation environments. Activity formats include Clinical Insights, Expert Perspective, Instructional Series Programming, Next-Generation Symposia, Patient-Case Approaches, including Simulation and Clinical Advances.
Summarizing selected highlights from the ADA annual congress 2020 with respect to the prevention of macrovascular complications in diabetes, the expert cardiologist Dr Mark Petrie from Glasgow, UK, reviews the top line results from the VERTIS trial with ertugliflozin, a new meta-analyis of SGLT2 inhibators, an update from DAPA-HF and the DEVOTE trial. He also comments on the findings from the HypoDeg CGM substudy in patients with type 1 diabetes, comparing the incidence of hypoglycemia of the second-generation basal insulin degludec with insulin glargine as well as emerging profile of the once weekly insulin icodec and pleotropic effects of GLP-1 RAs.
Made for: Diabetologists, Endocrinologists, Cardiologists, Primary Care Physicians
Disease areas: Diabetes
Developed by: Medscape
